- EQRX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
EQRx (EQRX) CORRESPCorrespondence with SEC
Filed: 5 Apr 21, 12:00am
CM Life Sciences III Inc.
c/o Corvex Management LP
667 Madison Avenue
New York, New York 10065
April 5, 2021
VIA EDGAR
Jeffrey Kauten
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | CM Life Sciences III Inc. | |
Registration Statement on Form S-1 | ||
Filed February 25, 2021 as amended | ||
File No. 333-253475 |
Dear Mr. Kauten:
Pursuant to Rule 461 of the rules and regulations promulgated under the Securities Act of 1933, as amended, CM Life Sciences III Inc. respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 4:00 p.m. Washington D.C. time on April 6, 2021, or as soon thereafter as practicable.
Please call Colin Diamond of White & Case LLP at (212) 819-8754 to provide notice of the effectiveness of the Registration Statement.
[Signature page follows]
Very truly yours, | ||
CM Life Sciences III Inc. | ||
By: | /s/ Brian Emes | |
Name: Brian Emes Title: Chief Financial Officer and Secretary |
cc: | Colin Diamond, White & Case LLP | |
Joel Rubinstein, White & Case LLP |
cc: | Gregg Noel, Skadden, Arps, Slate, Meagher & Flom LLP | |
Michael Mies, Skadden, Arps, Slate, Meagher & Flom LLP |
[Signature Page to Acceleration Request]